Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | CCND3 | P30281 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 5/20 | 0.53 |
| ▸ | CDK4 | P11802 | 6/20 | 0.52 |
| ▸ | CCND1 | P24385 | 6/20 | 0.52 |
| ▸ | CCND2 | P30279 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073760 | 0.87 | CCND3 (0.51) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6074091 | 0.86 | CCND3 (0.55) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6074532 | 0.86 | CCND3 (0.55) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6074010 | 0.82 | CDK2 (0.59) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6073819 | 0.81 | SYK (0.62) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6073505 | 0.79 | CCND3 (0.64) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6074138 | 0.78 | CDK2 (0.58) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL14633314 | 0.77 | CCND3 (0.50) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6073647 | 0.76 | CDK2 (0.56) | CDK2CCND3CCNA2CCNKCDK9 | |
| SCHEMBL6073923 | 0.76 | CCND3 (0.54) | CDK2CCND3CCNA2CCNKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | CDK2 5/4885CCND3 98/4885CCNA2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.